Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
• SemBioSys Eligible to Proceed With Phase I/II Plant-Produced Insulin Trial After Submission of IND
• Sanofi Aventis: New Real Life Studies Illustrate Greater A1C Lowering and Cost Benefit Observed With LANTUS(R) Over Detemir and NPH Insulin
• Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
• MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza
• Botaneco Receives Natural Ingredient Approval From ECOCERT(R) for Hydresia(TM) G2
• Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

News zu Wirtschaft, Politik, Finanzen, Gesundheit und Gold

Aktuelle News zu Wirtschaft, Finanzen, Politik, Gesundheit und Medizin und zu Gold und SemBioSys Submits IND for Safflower-Produced Insulin to U.S.FDA

Bankkaufmann - News

Das "Green Maturity Model" des Managementberatungs-, Technologie- u SemBioSys Submits IND for Safflower-Produced Insulin to U.S.FDA.29.07.2008

ots.at: das APA-OTS-Portal für multimediale Presseaussendungen

Phase I/II Plant-Produced Insulin Trial After Submission of IND SemBioSys Submits IND for Safflower-Produced Insulin to U.S.FDA = 29.07.2008 / 13:08

Presseportal: SemBioSys, Genetics Inc - SemBioSys erreicht wichtigen ...

to Proceed With Phase I/II Plant-Produced Insulin Trial After Submission of IND.29.07.08 13:06 SemBioSys Submits IND for Safflower-Produced Insulin to U.S.FDA

Presseportal: SemBioSys, Genetics Inc

to Proceed With Phase I/II Plant-Produced Insulin Trial After Submission of IND SemBioSys Submits IND for Safflower-Produced Insulin to U.S.FDA